Breaking News

Novasep Builds New Commercial API 

Facility

October 10, 2012

Invests $38.8 million in new plant in France

Novasep is investing $38.8 million to build a new plant at its Mourenx, France site to produce large volume commercial API. According to the company, the plant will be operational and validated within 18 months. The new plant will include Varicol systems with 1,200 mm diameter columns operated at up to 70 bars and will enable the production of a highly purified API from a complex mixture. The systems will also integrate solvent recovery systems for the recycling of 99.9% of solvents, according to the company.

This investment follows the opening of a new 2,000m2 facility in Shanghai, China and a $3.9 million investment to expand Highly Potent API (HPAPI) manufacturing capabilities at its facility in Le Mans, France.

"Demand for Novasep's advanced, purification-based manufacturing capabilities in the life science industries continues to increase as drugs in development and reaching the market become more complex and specific. This necessitates our third, and largest global plant expansion in 2012," said Patrick Glaser, president and chief executive officer of Novasep. "This successful project, the world's largest chromatography plant in the pharmaceutical industry, demonstrates the validity of the Novasep strategy which is based on the combination of synthesis, biosynthesis and purification. We thank our institutional partners for their active support and our shareholders for their strong involvement to enable this transforming project."

Related Contract Manufacturing:

  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks